You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Camrelizumab Plus Apatinib

Showing 1 - 25 of 607
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • TACE+Camrelizumab+Apatinib mesylate
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 17, 2022

Stage III Hepatocellular Cancer (CNLC Staging) Trial in Guangzhou (mFOLFOX7+Camrelizumab+Apatinib)

Recruiting
  • Stage III Hepatocellular Cancer (CNLC Staging)
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Jun 6, 2022

Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Camrelizumab, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • FOLFOX-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jan 19, 2022

Hepatocellular Carcinoma Trial in Guangzhou (camrelizumab& apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • camrelizumab& apatinib
  • Guangzhou, Guangzhou, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sep 18, 2022

Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

Recruiting
  • Chordoma
  • Chemotherapy Effect
  • camrelizumab and apatinib
  • Beijing, Beijing, China
    BEIJING
Nov 14, 2023

Advanced Biliary Tract Carcinoma Trial in Hangzhou (Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur)

Not yet recruiting
  • Advanced Biliary Tract Carcinoma
  • Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Jul 6, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • adebrelimab, camrelizumab plus apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Jun 21, 2023

Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Sep 8, 2022

Hepatocellular Carcinoma Trial in Hangzhou (PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • PVE+cTACE+Camrelizumab+Apatinib
  • cTACE+Atirizumab+Bevacizumab
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Feb 26, 2023

Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

Not yet recruiting
  • Locally Advanced Biliary Tract Cancer
  • Metastatic Biliary Tract Cancer
  • Camrelizumab and Apatinib Plus GP
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Feb 15, 2023

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)

Recruiting
  • Macrotrabecular Massive Hepatocellular Carcinoma
  • HAIC
  • Camrelizumab plus Apatinib
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023

Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Nov 16, 2022

Gestational Trophoblastic Neoplasia Trial in Beijing (Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B)

Recruiting
  • Gestational Trophoblastic Neoplasia
  • Camrelizumab plus apatinib CohortA
  • Camrelizumab plus apatinib Cohort B
  • Beijing, China
    Peking Union Medical College Hospital
Jul 7, 2022

Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)

Recruiting
  • Colon Cancer
  • Neoadjuvant Therapy
  • Camrelizumab , apatinib and chemotherapy
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Jan 27, 2023

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Recruiting
  • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Jan 4, 2023

Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Nov 6, 2022

Adrenocortical Carcinoma Trial (Camrelizumab)

Recruiting
  • Adrenocortical Carcinoma
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Dec 16, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Camrelizumab; Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Camrelizumab; Apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 30, 2021

Head and Neck Squamous Cell Carcinoma Trial (Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
  • (no location specified)
Dec 29, 2021

Hepatocellular Carcinoma Trial (Hepatectomy Combined With Camrelizumab and Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Hepatectomy Combined With Camrelizumab and Apatinib
  • Nanning, China
    Guangxi Medical University Cancer Hospital
Sep 4, 2022

Solid Tumor Trial in Henan (Camrelizumab combined with apatinib mesylate)

Recruiting
  • Solid Tumor
  • Camrelizumab combined with apatinib mesylate
  • Henan, China
    Henan Tumor Hospital
May 15, 2022